GlaxoSmithKline to Buy Stake in Intercell AG

GlaxoSmithKline Plc will buy a stake in Austria’s Intercell AG in a move that analysts said underscores drugmakers’ growing interest in vaccines. Glaxo will pay 33.6 million euros ($49.5 million) as part of the alliance to develop and market Intercell’s needle-free, patch-based immunizations for traveler’s diarrhea and pandemic influenza. The London-based drugmaker also will buy as much as 5 percent of Intercell for up to 84 million euros via a staggered shareholding option, the companies said in a statement today.

XTractor Premium - A Platform for discovery, knowledge sharing, analysis and modelling of published biomedical facts.









Comments

Popular posts from this blog

Abbott Laboratories Buys Piramal Healthcare Limited Biz for $3.72B

Top 25 Indian Bioinformatics Companies